Yoga in women undergoing treatment for breast cancer: Impact on quality of life in a randomized controlled trial.

Authors

null

Nita S. Nair

Department of Surgical Oncology, Breast Disease Management Group, Tata Memorial Centre (TMC), Mumbai, India

Nita S. Nair , Nishu Singh Goel , Rohini W Hawaldar , Shabina Siddique , Vani Parmar , Aarti Pandey , Rajendra A. Badwe

Organizations

Department of Surgical Oncology, Breast Disease Management Group, Tata Memorial Centre (TMC), Mumbai, India, Tata Memorial Centre, Mumbai, India

Research Funding

Other

Background: Yoga has been tested in multiple small-randomized studies for its impact on quality of life (QOL) on breast cancer (BC). We propose to study the effect of yoga on disease free survival as the primary endpoint in women with operable breast cancer. (Study methodology details refer to NCT02161900). Methods: Women with non-metastatic BC were randomized to yoga and conventional exercise (YCE) versus conventional exercise only (CE) in addition to standard therapy. Over and above documentation of recurrence and death, QOL was assessed in these women using the EORTC QLQC30, BR23, Brief fatigue inventory (BFI), Visual pain scores (VPS) and a spirituality questionnaire (SQ). EORTC QLQ was assessed at baseline (BL), 6-9 months (mo), 18-21 mo. BFI and VPS at BL, 6-8 mo and 12-15 mo and SQ at BL and 12-15 mo. We report the first interim analysis of QOL in 605 patients randomized to the study with atleast 1 year of follow up. The groups were balanced in both arms with respect to clinico-pathological factors. Results: At 6-9 mo (completion of adjuvant therapy), there was no significant difference in global QOL scores (p = 0.08), however 52% women on YCE showed an improvement from baseline compared to 42% in CE. At 18-21 mo emotional function scores were better in YCE (p = 0.002); with lesser systemic side effects in YCE arm (44% vs 56% p = NS). The median score of fatigue after adjuvant therapy measured by QLQ C30 was lower in YCE (17.37vs22.22, p = 0.003) which was similar to that observed by BFI at 12-15 mo (1.6vs 2, p = 0.04). Also in YCE there was lower reporting of detriment in general activity (41%vs 59%) and mood (34%vs66%) (p = NS). In VPS at 12-15mo, the median scores for pain intensity (p = 0.042), pain on movement (p = 0.038), pain on mobilization (p = 0.008) were lower in YCE. Lastly SQ assessed spirituality and showed no difference, but less deterioration compared to baseline scores in YCE. Conclusions: Yoga did not show a significant difference in global QOL but had a major benefit reaching statistical significance in fatigue, emotional score and pain. Yoga is a low-risk, low-cost complementary therapy that may improve compliance to therapy by improving parameters that can affect day-to-day activity in women with breast cancer. Clinical trial information: NCT02161900

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02161900

Citation

J Clin Oncol 35, 2017 (suppl; abstr 527)

DOI

10.1200/JCO.2017.35.15_suppl.527

Abstract #

527

Poster Bd #

127

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Yoga vs. behavioral placebo for fatigue and quality of life among older cancer survivors.

First Author: Evelyn Arana

Abstract

2024 ASCO Annual Meeting

Effects of a pilot 12-week exercise program on breast cancer survivors’ quality of life.

First Author: Lauren Imai

First Author: Anita Roselyn Peoples